Indonesia Pharma Outlook From IPMG Director Parulian Simanjuntak: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Indonesia is one of the least attractive pharma markets in Asia, with multinational companies facing major obstacles due to government restrictions and lack of transparency. Deficiencies in patent protection and a sizeable counterfeit industry make the situation even grimmer there. International Pharmaceutical Manufacturers' Group Executive Director Parulian Simanjuntak talked with PharmAsia News about the regulations that are putting a stranglehold on manufacturers in Indonesia and MNCs that might otherwise be thinking about entering Indonesia. IPMG, based in Jakarta, is the association for international pharmaceutical companies doing business in Indonesia.